Cambridge, MA, United States of America

Matthew Medeiros

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Servier Pharmaceuticals LLC. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Medeiros. Retrieved from https://idiyas.com/inventor/matthew-medeiros

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0


 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Matthew Medeiros

Introduction: Matthew Medeiros, a talented inventor based in Cambridge, MA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Matthew Medeiros holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and creativity.

Career Highlights: With a background in engineering and a passion for problem-solving, Matthew has successfully brought several cutting-edge inventions to life, revolutionizing industries and improving the lives of many.

Collaborations: Throughout his career, Matthew Medeiros has collaborated with leading research institutions, universities, and tech companies to further develop his inventions and bring them to the market, solidifying his reputation as a visionary inventor.

Conclusion: Matthew Medeiros continues to inspire the next generation of innovators with his remarkable work and dedication to pushing the boundaries of what is possible in the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…